albuterol sulfate inhalation aerosol / Generic mfg. - LARVOL DELTA

Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma (clinicaltrials.gov) - P=N/A | N=148 | Recruiting | Sponsor: Intech Biopharm Ltd. | Trial completion date: Apr 2024 ➔ Jun 2025 | Trial primary completion date: Mar 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

ARRIVAL: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Impact of nebulization versus metered-dose inhaler utilization on viral particle dispersion in patients with COVID-19. (PubMed, J Infect Prev) - "Adults infected with COVID-19 were enrolled and received a single dose of albuterol sulfate nebulized solution (2.5 mg/3 mL via breath-actuated nebulizer with filtered mouthpiece) or albuterol sulfate hydrofluoroalkane inhalation aerosol (90 µg/actuation; two puffs via MDI with spacer) in a randomized crossover sequence. In this first prospective trial evaluating viral load distribution following use of nebulizer versus MDI in hospitalized patients with COVID-19, low environmental contamination was found regardless of administration method. Findings support the use of either device when needed to treat patients with COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

In vitro performance of a combination beclomethasone dipropionate/salbutamol sulphate pressurised metered dose inhaler formulated with a low global warming potential propellant (BTS WM 2024) - "A next generation impactor (NGI) was used to determine FPD and MMAD whilst DD was ascertained with a dosage unit sampling apparatus (DUSA), respectively. View this table: View inline View popup Download powerpoint Abstract P46 Table 1 FPD, DD and MMAD for test combination and reference monoproduct formulations Conclusions The FPD, DD, and MMAD results of the test combination formulations were on/near-target based on monoproduct assessments of Qvar RediHaler and Proventil HFA, despite the change of propellant and combination of two drugs into one formulation."

Preclinical • Asthma • Immunology • Inflammation • Respiratory Diseases

MYCOBACTERIUM CHELONAE-ASSOCIATED BRONCHIECTASIS IN AN IMMUNOCOMPETENT HOST: A RARE PRESENTATION (CHEST 2024) - "Consequently, she was initiated on a bronchial hygiene regimen including albuterol HFA, 7% hypertonic saline, Aerobika, huff cough, and saline sinus rinses with distilled water, without starting an antibiotic regimen after a thorough discussion of risks versus benefits. The isolation of Mycobacterium chelonae in an immunocompetent host represents a rare occurrence, particularly in the context of bronchiectasis without predisposing factors. It underscores the critical importance of considering even the most uncommon pathogens in patients with atypical respiratory presentations. The successful management of this case, focusing on bronchial hygiene without the necessity for antibiotic therapy, further illustrates the importance of a tailored approach in the treatment of rare infectious diseases."

Alpha-1 Antitrypsin Deficiency • Bronchiectasis • Cough • Cystic Fibrosis • Genetic Disorders • Hepatology • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • DNAH9 • FLCN

ARRIVAL: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma (clinicaltrials.gov) - P=N/A | N=148 | Recruiting | Sponsor: Intech Biopharm Ltd. | Trial completion date: Jun 2023 ➔ Apr 2024 | Trial primary completion date: May 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: Cipla Ltd.

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Effect of Pulmonary Rehabilitation Exercise on Lung Volume and Respiratory Muscle Recovery in Lung Cancer Patients Undergoing Lobectomy. (PubMed, Altern Ther Health Med) - "The EG received inhalation therapy with albuterol sulfate nebulizer solution and personalized pulmonary rehabilitation exercise training, while the CG received nebulized treatment alone. However, this work was subjected to several limitations, including a relatively short duration, necessitating longer-term follow-up to assess long-term effects. Additionally, the sample size was relatively small, and further large-scale research was needed to validate these findings."

Journal • Lung Cancer • Oncology • Pulmonary Disease • Solid Tumor

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs (clinicaltrials.gov) - P=N/A | N=220 | Recruiting | Sponsor: University of Florida | Trial completion date: Jul 2023 ➔ Jul 2033 | Trial primary completion date: Jul 2023 ➔ Jul 2032

Trial completion date • Trial primary completion date • Alpha-1 Antitrypsin Deficiency • Cystic Fibrosis • Fibrosis • Genetic Disorders • Hepatology • Immunology • Pulmonary Disease • Respiratory Diseases • CRP

ARGARG: Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes (clinicaltrials.gov) - P=N/A | N=89 | Completed | Sponsor: Columbia University | Unknown status ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Intech Biopharm Ltd. | Active, not recruiting ➔ Completed

Trial completion

Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Intech Biopharm Ltd. | Active, not recruiting ➔ Completed

Trial completion

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs (clinicaltrials.gov) - P=N/A | N=220 | Recruiting | Sponsor: University of Florida | Trial completion date: Aug 2022 ➔ Jul 2023 | Trial primary completion date: Aug 2022 ➔ Jul 2023

Trial completion date • Trial primary completion date • Alpha-1 Antitrypsin Deficiency • Cystic Fibrosis • Fibrosis • Genetic Disorders • Hepatology • Immunology • Pulmonary Disease • Respiratory Diseases • CRP

Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma (clinicaltrials.gov) - P=N/A | N=148 | Recruiting | Sponsor: Intech Biopharm Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2021 ➔ Jun 2023 | Trial primary completion date: Dec 2021 ➔ May 2023

Enrollment open • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Aurobindo Pharma Ltd | N=110 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions (clinicaltrials.gov) - P=N/A | N=60 | Active, not recruiting | Sponsor: Intech Biopharm Ltd.

New trial

Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation (clinicaltrials.gov) - P3 | N=110 | Not yet recruiting | Sponsor: Aurobindo Pharma Ltd

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19 (clinicaltrials.gov) - P=N/A | N=14 | Completed | Sponsor: Theravance Biopharma | Recruiting ➔ Completed | N=10 ➔ 14

Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19 (clinicaltrials.gov) - P=N/A; N=10; Recruiting; Sponsor: Theravance Biopharma; Trial completion date: Sep 2021 ➔ Dec 2021; Trial primary completion date: Sep 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

"آلبوترول دارویی است که باعث باز شدن مجاری تنفسی می‌شود. این دارو تحت برندهای دیگری نیز به بازار عرضه می‌شود که نام های دیگر آن عبارتند از: ProAir HFA, ProAir RespiClick, Proventil HFA, Ventolin HFA..از وجود انسولین قلمی در داروخانه‌ّا اطمینان حاصل کنید@merck #blurrywyesight" (@alidoki1)

"Albuterol HFA, epi-pen, doxycycline" (@owlblazek)

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs (clinicaltrials.gov) - P=N/A; N=220; Recruiting; Sponsor: University of Florida; Trial completion date: Aug 2021 ➔ Aug 2022; Trial primary completion date: Aug 2021 ➔ Aug 2022

Trial completion date • Trial primary completion date • Alpha-1 Antitrypsin Deficiency • Cystic Fibrosis • Fibrosis • Genetic Disorders • Hepatology • Immunology • Pulmonary Disease • Respiratory Diseases • AAT • CRP

Effects of Environmental and Mechanical Variations on Particle Size Distribution of Albuterol HFA Inhalers. (PubMed, Respir Care) - "Temperature made a difference, with cold inhalers producing a lower fine-particle fraction. The early portion of the inhaler had a better fine-particle fraction than the middle and end of the inhaler's lifespan. We could not demonstrate that shaking the inhaler had a significant effect on the fine-particle fraction. Submerging the inhaler in water significantly reduced the fine-particle fraction."

Journal

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19 (clinicaltrials.gov) - P=N/A; N=10; Recruiting; Sponsor: Theravance Biopharma; Trial completion date: Apr 2021 ➔ Sep 2021; Initiation date: Feb 2021 ➔ May 2021; Trial primary completion date: Apr 2021 ➔ Sep 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease